Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Childrens Oncology Group Randomized Trial Pediatric Oncology Group 9404 [Pediatric Oncology]
Conclusion
Dexrazoxane was cardioprotective and did not compromise antitumor efficacy, did not increase the frequencies of toxicities, and was not associated with a significant increase in second malignancies with this doxorubicin-containing chemotherapy regimen. We recommend dexrazoxane as a cardioprotectant for children and adolescents who have malignancies treated with anthracyclines.
Source: Journal of Clinical Oncology - Category: Cancer & Oncology Authors: Asselin, Devidas, Chen, Franco, Pullen, Borowitz, Hutchison, Ravindranath, Armenian, Camitta, Lipshultz Tags: Chemotherapy, Chemotherapy, Non-Hodgkin's Lymphoma, Acute Lymphoblastic Leukemia, Long Term Survival & Late Effects, Outcomes Research, Supportive Care Pediatric Oncology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Armenia Health | Cancer & Oncology | Cardiology | Chemotherapy | Children | Heart | Hematology | Leukemia | Lymphoma | Non-Hodgkin's Lymphoma | Pediatrics | Toxicology